Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALNY save search
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
Published: 2022-10-24 (Crawled : 20:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.12%
H: 2.54%
C: 1.26%
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.53%
H: 5.32%
C: 5.2%
conference financial results
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.55%
H: 2.68%
C: 1.2%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.26%
vir-2218 treatment hepatitis vir-3434 virus trial infection phase 2
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Published: 2022-09-20 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.18%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: -1.85%
amvuttra treatment europe approval
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
Published: 2022-09-19 (Crawled : 13:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.98%
H: 2.44%
C: 2.41%
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
Published: 2022-09-13 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.97%
H: 0.16%
C: -0.98%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.77%
H: 0.54%
C: -0.8%
america meeting heart study
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes - September 13, 2022
Published: 2022-09-13 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.97%
H: 0.16%
C: -0.98%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.77%
H: 0.54%
C: -0.8%
offering
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
Published: 2022-09-12 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -3.75%
H: 0.52%
C: -1.34%
offering
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-09-08 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.67%
H: 10.61%
C: 10.19%
positive results study
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
Published: 2022-09-06 (Crawled : 14:00) - biospace.com/
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: 0.41%
H: 0.1%
C: -1.87%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.51%
H: 0.22%
C: -1.54%
global conference presentation
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.64%
H: 1.24%
C: 0.07%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.56%
H: 1.41%
C: -0.34%
treatment nephropathy positive study phase 2
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
Published: 2022-08-24 (Crawled : 21:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.0%
H: 3.6%
C: 1.66%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 1.26%
H: 3.73%
C: 0.62%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.44%
H: 2.9%
C: 1.45%
ADAP | $0.8984 -8.98% -9.86% 3.3M
|
Health Technology
|
| O: 0.46%
H: 5.04%
C: 1.83%
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
Published: 2022-08-18 (Crawled : 12:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -5.88%
H: 3.23%
C: 3.23%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.38%
H: 0.39%
C: -0.23%
symposium international study
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-11 (Crawled : 22:00) - globenewswire.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.0%
H: 3.23%
C: 1.94%
update results
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Published: 2022-08-11 (Crawled : 14:20) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.42%
H: 0.6%
C: -0.28%
RPRX | $27.885 1.0% 0.99% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.5%
C: -0.5%
NVCR | $12.04 -0.08% -0.08% 1.4M
|
Health Technology
|
| O: 0.85%
H: 5.47%
C: 2.45%
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: -1.2%
H: 2.6%
C: -3.36%
BEAM | $24.33 0.08% 0.08% 1.7M
|
Health Technology
|
| O: 1.31%
H: 10.03%
C: -0.75%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.04%
H: 1.13%
C: -1.08%
AGIO | News | $29.43 1.38% 1.36% 550K
|
Health Technology
|
| O: 0.28%
H: 0.71%
C: -8.16%
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Published: 2022-08-09 (Crawled : 23:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.76%
H: 2.0%
C: -2.34%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.17%
H: 0.5%
C: -3.03%
update results
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 47.44%
H: 0.0%
C: 0.0%
topline positive results study
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
Published: 2022-07-28 (Crawled : 12:20) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -3.5%
H: 6.04%
C: 4.76%
results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.